With the continuous development of technology, we can use single-cell scRNA-seq can explore gene expression profiles and predict drugs through protein-protein interactions and molecular docking, for example, it has been found that NLRP3 inhibitors show stronger atheroprotective activity against atherosclerosis in chimeric mice recombinantly reconstituted with Tet methylcytosine dioxygenase 2-deficient cells, the DB05490 may act as a potential inhibitor of hematopoietic stem cell-associated genes, and both drugs may be used as therapeutic agents for MI. Here, NLRP3 is linked to atherosclerosis.